Am Fam Physician. 2022;105(6):665-666
Author disclosure: No relevant financial relationships.
Multiparametric magnetic resonance imaging (mpMRI) is a specific MRI test used to detect and evaluate prostate cancer. It requires additional radiologist training and sequences not routinely performed in anatomic imaging, such as diffusion-weighted and dynamic contrast-enhanced imaging.1 The National Comprehensive Cancer Network and the American Urological Association support using mpMRI for risk stratification before the first prostate biopsy, to perform targeted prostate biopsy, and in active surveillance.2,3
| Test | Indication | Population and frequency | Cost* |
|---|---|---|---|
| Multiparametric magnetic resonance imaging | Risk stratification for targeted biopsy; active surveillance of low-risk prostate cancer | Patients 50 years or older with suspected or known prostate cancer, frequency of test varies | $275 to $444 |
Already a member/subscriber?
Log In
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
Purchase Access:
Learn More
